Indications
Myqorzo is indicated for the treatment of symptomatic (New York Heart Association, NYHA, class II-III) obstructive hypertrophic cardiomyopathy (oHCM) in adult patients.
Composition
- Active substance
- aficamten
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Myqorzo
- Active substance
- aficamten
- Therapeutic area
- Cardiomyopathy, Hypertrophic
- Marketing authorisation holder
- Cytokinetics (Ireland) Limited
- Status
- Authorised
- EU authorisation
- 12 Feb 2026
- EMA product number
- EMEA/H/C/006228
EMA designations
- Orphan medicine
- No
- Conditional approval
- No
- Biosimilar
- No
- Generic
- No
- Accelerated assessment
- No
- Additional monitoring
- Yes
- Patient safety information
- No